May 11, 2023 / 03:55PM GMT
Jason Eron Zemansky - BofA Securities, Research Division - VP
Good afternoon. Thank you so much for joining us. My name is Jason Zemansky. I'm one of the new SMID cap biotech analyst here at BofA, welcoming everyone to this, our final morning. Very pleased to be able to introduce Zymeworks and the Chair and CEO, Ken Galbraith, which is here with us today. Ken, thank you so much for joining me.
Kenneth H. Galbraith - Zymeworks Inc. - CEO & Chairman of the Board
No, Jason, thanks for the invitation to come to Las Vegas and attend your conference.
Questions and Answers:
Jason Eron Zemansky - BofA Securities, Research Division - VPWonderful. Well, maybe let's start off a little bit more broadly for those who maybe aren't as familiar with the story and the platform. Can you talk a little bit about your platform, what separates your multi-specific antibody technology from competitors? And how is the ADC platform differentiated?
Kenneth H. Galbraith - Zymeworks Inc. - CEO &
Trustpilot
